What Is Retatrutide?
Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide developed by Eli Lilly. It simultaneously activates three distinct metabolic receptor pathways. A fatty acid side chain extends circulating half-life to approximately six days per published pharmacokinetic studies, enabling once-weekly administration in clinical trial protocols. Molecular weight is approximately 4816 Da. The compound is not approved by Health Canada, the FDA, or any regulatory body for human therapeutic use as of 2026.
Triple Receptor Mechanisms
- GLP-1 Receptor: Stimulates glucose-dependent insulin secretion, slows gastric emptying, and modulates appetite signaling across pancreatic beta cells, hypothalamic neurons, and gastrointestinal enteroendocrine cells. GLP-1 receptor agonism is the shared mechanism with semaglutide.
- GIP Receptor: Enhances insulin secretion and influences adipose tissue metabolism, complementing GLP-1 activity. GIP agonism is shared with tirzepatide (dual GIP/GLP-1). At adipocyte level, GIP signaling may also influence lipolysis regulation and fat storage dynamics.
- Glucagon Receptor: Increases hepatic fatty acid oxidation and resting energy expenditure — the pharmacologically distinct feature that differentiates Retatrutide from prior single and dual agonists. Glucagon agonism raises theoretical concerns about hepatic glucose output that are mitigated in the triple-agonist context by concurrent GLP-1 and GIP activity modulating insulin secretion.
Phase 2 Clinical Trial Literature (NEJM 2023)
> The figures below summarize third-party human clinical trial data conducted by the drug's developer under regulatory oversight. They are reported here for scientific and educational context only. They are not representative of, or claims about, any product sold by Lux BioPure — our materials are research chemicals for in vitro laboratory use and are not for human consumption.
The Phase 2 trial published in the New England Journal of Medicine reported the following endpoints across the referenced dose cohorts and timepoints:
| Compound | Mechanism | Reported endpoint (per publication) |
|---|---|---|
| Semaglutide | GLP-1 mono-agonist | ~15% (68 wks) |
| Tirzepatide | GLP-1 + GIP | ~20.9% (72 wks) |
| Retatrutide | GLP-1 + GIP + glucagon | ~24% (48 wks) |
These trials used different durations and designs, so the values are not directly comparable — the varying timepoints (48 vs. 68 vs. 72 weeks) are a methodological caveat, not a ranking. The reported adverse events (nausea, vomiting, diarrhea) were dose-dependent and consistent with the GLP-1 agonist class profile. All figures reflect the published trial record for an investigational compound, not outcomes attributable to any purchasable material.
Phase 3 Program Status (2026)
As of 2026, Retatrutide is advancing through Eli Lilly's TRIUMPH Phase 3 clinical program. Phase 3 trials are evaluating efficacy and safety across obesity, type 2 diabetes, and cardiovascular risk reduction endpoints. Phase 3 enrollment and interim data readouts are ongoing; regulatory approval timelines remain dependent on trial outcomes and regulatory review processes.
Retatrutide remains an investigational compound with no current regulatory approval for human therapeutic use in any jurisdiction.
Pharmacokinetics Relevant to Research Design
The ~6-day half-life enables once-weekly dosing in research protocols. This extended half-life derives from the fatty acid side chain enabling albumin binding, similar to the mechanism used in semaglutide's pharmacokinetic design. Steady-state plasma concentrations are reached after approximately 4–6 weeks of once-weekly dosing. The retatrutide reconstitution calculator converts a chosen vial concentration into working-solution volumes for bench preparation.
For preclinical in vitro research, the relevant pharmacological parameters are receptor binding affinities at GLP-1R, GIPR, and GCGR. Retatrutide demonstrates balanced agonism across all three receptors, distinguishing it mechanistically from biased agonists under development in the incretin space.
Research Applications in 2026
Canadian researchers working with Retatrutide explore several avenues:
Receptor pharmacology: GLP-1R, GIPR, and GCGR expression studies; receptor activation kinetics; downstream cAMP and signaling cascade characterization.
Comparative incretin biology: Side-by-side mechanism comparisons with semaglutide and tirzepatide to understand the marginal contribution of glucagon receptor agonism to metabolic outcomes.
Adipose tissue metabolism: GIP and glucagon receptor co-activation effects on adipocyte differentiation, lipid metabolism, and thermogenic gene expression.
Hepatic fatty acid metabolism: Glucagon receptor-mediated effects on hepatic lipid oxidation pathways in the context of balanced incretin co-agonism.
Protocol Design Considerations
Research designs using Retatrutide should account for:
- Receptor selectivity confirmation: Verify using validated GLP-1R, GIPR, and GCGR antagonists (e.g., exendin 9-39 for GLP-1R) to pharmacologically dissect contributions of each receptor in cellular assays.
- Concentration selection: Align in vitro concentrations with published Ki values at each receptor target; avoid supraphysiological concentrations that may produce off-target effects.
- Cell model selection: Pancreatic beta cell lines (MIN6, INS-1), adipocyte models (3T3-L1), and hepatocyte models (HepG2, primary hepatocytes) are relevant depending on the mechanistic question.
- Stability: As a larger fatty-acid-modified peptide, reconstituted Retatrutide should be handled with standard peptide storage precautions: 2–8°C for active use, −20°C for long-term storage; avoid repeated freeze-thaw cycles.
Quality Standards for Research-Grade Retatrutide
Given Retatrutide's structural complexity (39 amino acids with fatty acid modification), quality verification is particularly important:
- HPLC purity ≥98%; the fatty acid modification creates additional impurity pathways relative to unmodified peptides
- Mass spectrometry confirmation at approximately 4816 Da (see how to read a Certificate of Analysis)
- Batch-specific documentation rather than generic certificates
- Third-party independent laboratory verification is strongly recommended for a compound of this complexity
Canadian Sourcing
Retatrutide is available from select Canadian research chemical suppliers with the analytical capability to produce and verify complex fatty-acid-modified peptides. Availability is more limited than established compounds like BPC-157 or semaglutide. Pricing reflects synthesis complexity, with 2 mg vials typically ranging CAD $150–$250 from quality domestic suppliers.
Frequently Asked Questions
What makes retatrutide different from semaglutide and tirzepatide? Retatrutide (LY3437943) is a synthetic 39-amino-acid triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors. Semaglutide is a single GLP-1 agonist and tirzepatide is a dual GLP-1/GIP agonist; the added glucagon-receptor activity is the pharmacologically distinct feature differentiating retatrutide from prior single and dual agonists.
Is retatrutide approved for use? No. Retatrutide remains an investigational compound with no regulatory approval for human therapeutic use in any jurisdiction as of 2026. It is advancing through Eli Lilly's TRIUMPH Phase 3 program, and it is available only as a research chemical for in vitro and preclinical laboratory research.
Why is quality verification especially important for retatrutide? Retatrutide's structural complexity — 39 amino acids with a fatty acid modification — creates additional impurity pathways relative to unmodified peptides. Confirm HPLC purity of at least 98%, mass spectrometry confirmation at approximately 4816 Da, and batch-specific documentation. Third-party independent laboratory verification is strongly recommended for a compound of this complexity.
How should retatrutide be handled in the lab? As a larger fatty-acid-modified peptide, reconstituted retatrutide should follow standard peptide storage precautions: 2–8°C for active use and −20°C for long-term storage, avoiding repeated freeze-thaw cycles. Its roughly six-day half-life derives from fatty-acid-enabled albumin binding.
Research Disclaimer
Retatrutide is not approved by Health Canada or any regulatory authority for human or veterinary therapeutic use. It is available exclusively for in vitro and preclinical laboratory research by qualified researchers. This content does not constitute medical advice.